nach oben

Medical Oncology

Erschienen in:

01.06.2018 | Review Article

Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors

verfasst von: Vishal Jindal, Ena Arora, Sorab Gupta

Erschienen in: Medical Oncology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Chimeric antigen receptor (CAR) T cell therapy is a novel and innovative immunotherapy. CAR-T cells are genetically engineered T cells, carrying MHC independent specific antigen receptor and co-stimulatory molecule which can activate an immune response to a cancer specific antigen. This therapy showed great results in hematological malignancies but were unable to prove their worth in solid tumors. Likely reasons for their failure are lack of antigens, poor trafficking, and hostile tumor microenvironment. Excessive amount of research is going on to improve the efficacy of CAR T cell therapy in solid tumors. In this article, we will discuss the challenges faced in improving the outcome of CAR T cell therapy in solid tumors and various strategies adopted to curb them.

Sadelain M, Brentjens R, Rivière I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388–98.CrossRefPubMedPubMedCentral

Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121:1822–6.CrossRefPubMedPubMedCentral

Zhao Y, Wang QJ, Yang S, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol. 2009;183:5563–74.CrossRefPubMed

Zhong XS, Matsushita M, Plotkin J, et al. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8* T cell-mediated tumor eradication. MolTher. 2010;18:413–20.

Wilkie S, Picco G, Foster J, et al. Re-targeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol. 2008;180:4901–9.CrossRefPubMed

Yeku OO, Brentjens RJ. Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy. Biochem Soc Trans. 2016;44:412–8.CrossRefPubMedPubMedCentral

Suarez ER, Chang K, Sun J, et al. Chimeric antigen receptor T cells secreting anti–PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016;7:34341–55.CrossRefPubMedPubMedCentral

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17.CrossRefPubMedPubMedCentral

Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Med Sci Transl. 2015;7:303ra139.CrossRef

10.

Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, et al. Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med. 2015;373:1040–7.CrossRefPubMedPubMedCentral

11.

Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517–28.CrossRefPubMed

12.

Yu S, Li A, Liu Q, Li T, Yuan X, Han X, et al. Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol 2017;10(1):78. https://doi.org/10.1186/s13045-017-0444-9.CrossRefPubMedPubMedCentral

13.

Hynes NE, MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 2009;21(2):177–84. https://doi.org/10.1016/j.ceb.2008.12.010 53.CrossRefPubMed

14.

Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5(5):341–54. https://doi.org/10.1038/nrc166754.CrossRefPubMed

15.

Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19(13):3159–67. https://doi.org/10.1093/emboj/19.13.3159.CrossRefPubMedPubMedCentral

16.

Yano S, Kondo K, Yamaguchi M, Richmond G, Hutchison M, Wakeling A, et al. Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res. 2002;23(5A):3639–50. 56.

17.

Sasada T, Azuma K, Ohtake J, Fujimoto Y. Immune responses to epidermal growth factor receptor (EGFR) and their application for cancer treatment. Front Pharmacol. 2016;7:405. https://doi.org/10.3389/fphar.2016.0040557.CrossRefPubMedPubMedCentral

18.

Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist. 2002;7(Suppl 4):31–9.CrossRefPubMed

19.

Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, et al. Prognostic value of epidermal growth factor receptor in patients with glio-blastomamultiforme. Cancer Res. 2003;63(20):6962–70. 59.PubMed

20.

Frederick L, Wang X-Y, Eley G, James CD. Diversity and frequency of epider-mal growth factor receptor mutations in human glioblastomas. Cancer Res. 2000;60(5):1383–7. 60.PubMed

21.

Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 1992;89(7):2965–9. https://doi.org/10.1073/pnas.89.7.2965.CrossRefPubMedPubMedCentral

22.

Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGettigan SE, et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. 2015;7(275):275ra22. https://doi.org/10.1126/scitranslmed.aaa4963.CrossRefPubMedPubMedCentral

23.

Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther. 2012;23(10):1043–53. https://doi.org/10.1089/hum.2012.041.CrossRefPubMedPubMedCentral

24.

O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 2017;9(399). https://doi.org/10.1126/scitranslmed.aaa098468.

25.

Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY. Receptor for inter-leukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res. 1999;5(5):985–90. 70.PubMed

26.

Brown CE, Warden CD, Starr R, Deng X, Badie B, Yuan YC, et al. Glioma IL13Ralpha2 is associated with mesenchymal signature gene expression and poor patient prognosis. PLoS ONE 2013;8(10):e77769. https://doi.org/10.1371/journal.pone.007776971.CrossRefPubMedPubMedCentral

27.

Thaci B, Brown CE, Binello E, Werbaneth K, Sampath P, Sengupta S. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro Oncol. 2014;16(10):1304–12. https://doi.org/10.1093/neuonc/nou045.CrossRefPubMedPubMedCentral

28.

Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375(26):2561–9. https://doi.org/10.1056/NEJMoa1610497.CrossRefPubMedPubMedCentral

29.

Bielamowicz K, Fousek K, Byrd TT, Samaha H, Mukherjee M, Aware N, et al. Trivalent CAR T-cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 2017. https://doi.org/10.1093/neuonc/nox182.CrossRefPubMedCentral

30.

Park JR, DiGiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lym-phocyte clones in patients with neuroblastoma. Mol Ther. 2007;15(4):825–33. https://doi.org/10.1038/sj.mt.6300104.CrossRefPubMed

31.

Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006;12(20):6106–15. https://doi.org/10.1158/1078-0432.CCR-06-1183.CrossRefPubMedPubMedCentral

32.

Riese MJ, Wang LC, Moon EK, Joshi RP, Ranganathan A, June CH, et al. Enhanced effector responses in activated CD8 + T cells deficient in diacy-lglycerol kinases. Cancer Res 2013;73(12):3566–77. https://doi.org/10.1158/0008-5472.CAN-12-3874.CrossRefPubMedPubMedCentral

33.

Shen H, Laird PW. Interplay between the cancer genome and epigenome. Cell. 2013;153:38–55.CrossRefPubMedPubMedCentral

34.

Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids 2013;9(2):32. https://doi.org/10.1038/mtna.2013.3224.CrossRef

35.

Chinnasamy D, Tran E, Yu Z, Morgan RA, Restifo NP, Rosenberg SA. Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. Cancer Res. 2013;73(11):3371–80. https://doi.org/10.1158/0008-5472. CAN-12-3913.CrossRefPubMedPubMedCentral

36.

Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira ACP, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012;32:1059–70.CrossRefPubMed

37.

Kloss CC, Condomines M, Cartellieri M, Bachmann M, Sadelain M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat Biotechnol. 2013;31:71 – 5.CrossRefPubMed

38.

Caruso HG, Hurton LV, Najjar A, Rushworth D, Ang S, Olivares S, et al. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Res. 2015;75:3505–18.CrossRefPubMedPubMedCentral

39.

Jones BS, Lamb LS, Goldman F, Di Stasi A. Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol. 2014;5.

40.

Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5.

41.

Ciceri F, Bonini C, Stanghellini MTL, Bondanza A, Traversari C, Salomoni M, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidenticalhaemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II study. Lancet Oncol. 2009;10:489–500.CrossRefPubMed

42.

Slaney CY, Kershaw MH, Darcy PK. Trafficking of T Cells into Tumors. Cancer Res. 2014;74:7168–74.CrossRefPubMed

43.

Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, Aboody KS, et al. Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol. 2007;179(5):3332–41. https://doi.org/10.4049/jimmunol.179.5.3332.CrossRefPubMed

44.

Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM, et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother (Hagerstown:1997). 2010;33:780.CrossRef

45.

Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood. 2009;113:6392 – 402.CrossRefPubMedPubMedCentral

46.

Moon EK, Carpenito C, Sun J, Wang L-CS, Kapoor V, Predina J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin- specific chimeric antibody receptor. Clin Cancer Res. 2011;17(14):4719–30. https://doi.org/10.1158/1078-0432.CCR-11-0351.CrossRefPubMedPubMedCentral

47.

Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009;113(25):6392–402. https://doi.org/10.1182/blood-2009-03-209650.CrossRefPubMedPubMedCentral

48.

49.

Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer. 2005. https://doi.org/10.1038/nrc1750. 5:965 – 76; PMID ;.PubMedCrossRef

50.

Nishio N, Dotti G. Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors. Oncoimmunology. 2015;4(2):e988098. https://doi.org/10.4161/21505594.2014.988098.CrossRefPubMedPubMedCentral

51.

Nishio N, Diaconu I, Liu H, Cerullo V, Caruana I, Hoyos V, et al. Armed oncolytic virus enhances immune functions of chimeric antigen receptor– modified T cells in solid tumors. Cancer Res. 2014;74(18):5195–205. https://doi.org/10.1158/0008-5472.CAN-14-0697.CrossRefPubMedPubMedCentral

52.

Bernfield M, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999;68:729–77.CrossRefPubMed

53.

de Mestre AM, Staykova MA, Hornby JR, Willenborg DO, Hulett MD. Expression of the heparan sulfate-degrading enzyme heparanase is induced in infiltrating CD4 + T cells in experimental autoimmune encephalomyelitis and regulated at the level of transcription by early growth response gene 1. J Leukoc Biol. 2007;82:1289–300.CrossRefPubMed

54.

Vlodavsky I, Ilan N, Naggi A, Casu B. Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr Pharm Des. 2007;13:2057–73. 14.CrossRefPubMed

55.

Yurchenco PD, Schittny JC. Molecular architecture of basement membranes. FASEB J. 1990;4:1577–90.CrossRefPubMed

56.

Caruana I, Savoldo B, Hoyos V, Weber G, Liu H, Kim ES, et al. Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lym-phocytes. Nat Med. 2015;21(5):524–9. https://doi.org/10.1038/nm.3833.CrossRefPubMedPubMedCentral

57.

Yaghoubi SS, Jensen MC, Satyamurthy N, Paik D, Czernin J, Gambh SS. Non-invasive detection of therapeutic cytolytic T Cells in patients with [18-F]FHBG positron emission tomography in a glioma patient.Nat. Clin Pract Oncol. 2009;6:53–8.CrossRef

58.

Brown CE, Badie B, Barish ME, Weng L, Julie R, Chang W, Naranjo A, Starr R, Wagner J, Wright C, et al. Bioactivity and safety of IL13Ra2-redirected chimeric antigen receptor CD8 + T cells inpatients with recurrent glioblastoma. Clin Cancer Res. 2016;21:4062–72.CrossRef

59.

Brown CE, Alizadeh D, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, Kurien A, Priceman SJ, Wang X, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375:2561–9.CrossRefPubMedPubMedCentral

60.

Katz SC, Burga RA, Mccormack E, Wang LJ, Mooring W, Point G, Khare PD, Thorn M, Ma Q, Stainken BF, et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigenreceptor modified T cell therapy for CEA + liver metastases. Clin Cancer Res. 2015;21:3149–59.CrossRefPubMedPubMedCentral

61.

Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in humanneoplasia: rationale and promise. Cancer Cell. 2003;4:431–6.CrossRefPubMed

62.

Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, Ohta A, Thiel M. Physiological control of immune response and inflammatorytissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol. 2004;22:657–82.CrossRefPubMed

63.

Newick K, O’Brien S, Sun J, Kapoor V, Maceyko S, Lo A, et al. Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase A localization. Cancer Immunol Res. 2016;4(6):541–51. https://doi.org/10.1158/2326-6066. CIR-15-0263.CrossRefPubMedPubMedCentral

64.

Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. FEBS Lett. 1995;358:1–3.CrossRefPubMed

65.

Ligtenberg MA, Mougiakakos D, Mukhopadhyay M, Witt K, Lladser A, Chmielewski M, et al. Coexpressed catalase protects chimeric antigen receptor–redirected T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity. J Immunol. 2016;196(2):759–66. https://doi.org/10.4049/jimmunol.1401710.CrossRefPubMed

66.

Hirata F, Ohnishi T, Hayaishi O. Indoleamine 2,3-dioxygenase. Characterization and properties of enzyme. O2- complex. J BiolChem. 1977;252(13):4637–42.

67.

Friberg M, Jennings R, Alsarraj M, et al. Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer. 2002;101(2):151–5.CrossRefPubMed

68.

Frumento G, Rotondo R, Tonetti M, Damonte G, Benatti U, Ferrara GB. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med. 2002;196(4):459–68.CrossRefPubMedPubMedCentral

69.

Opitz CA, Litzenburger UM, Sahm F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011;478(7368):197–203.CrossRefPubMed

70.

Ninomiya S, Hara T, Tsurumi H, et al. Indoleamine 2,3-dioxygenase in tumor tissue indicates prognosis in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol. 2011;90(4):409–16.CrossRefPubMed

71.

Ninomiya S, Hara T, Tsurumi H, et al. Indoleamine 2,3-dioxygenase expression and serum kynurenine concentrations in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;53(6):1143–5.CrossRefPubMed

72.

Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, Heslop HE, Brenner MK, Rooney CM, Ramos CA. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepletingdrugs. Blood. 2015;125(25):3905–16. https://doi.org/10.1182/blood-2015-01-621474.CrossRefPubMedPubMedCentral

73.

Schönbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001;58:4–43.CrossRefPubMed

74.

Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996;184:747–52.CrossRefPubMed

75.

Clarke SR. The critical role of CD40/CD40L in the CD4-dependent generation of CD8 + T cell immunity. J Leukoc Biol. 2000;67:607–14.CrossRefPubMed

76.

Cayabyab M, Phillips JH, Lanier LL. CD40 preferentially costimulates activation of CD4 + T lymphocytes. J Immunol. 1994;152:1523–31.PubMed

77.

Peng X, Kasran A, Warmerdam PA, de Boer M, Ceuppens JL. Accessory signaling by CD40 for T cell activation: induction of Th1 and Th2 cytokines and synergy with interleukin-12 for interferon-gamma production. Eur J Immunol. 1996;26:1621–7.CrossRefPubMed

78.

Curran KJ, Seinstra BA, Nikhamin Y, et al. Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. Mol Ther. 2015;23(4):769–78. https://doi.org/10.1038/mt.2015.4.CrossRefPubMedPubMedCentral

79.

Leivonen SK, Kahari VM. Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer. 2007;121(10):2119–24. https://doi.org/10.1002/ijc.23113.CrossRefPubMed

80.

Rubtsov YP, Rudensky AY. TGFbetasignalling in control of T-cell-mediated self-reactivity. Nat Rev Immunol. 2007;7(6):443–53. https://doi.org/10.1038/nri2095.CrossRefPubMed

81.

Chen ML, et al. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci USA. 2005;102(2):419–24. https://doi.org/10.1073/pnas.0408197102.CrossRefPubMed

82.

Li MO, Sanjabi S, Flavell RA. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity. 2006;25(3):455–71. https://doi.org/10.1016/j.immuni.2006.07.011.CrossRefPubMed

83.

Lacuesta K, et al. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother. 2006;29(3):250–60. https://doi.org/10.1097/01.cji.0000192104.24583.CrossRefPubMed

84.

Wang L, et al. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8 + T cells. Clin Cancer Res. 2010;16(1):164–73. https://doi.org/10.1158/1078-0432.CCR-09-1758.CrossRefPubMed

85.

Quatromoni JG, Wang Y, Vo DD, et al. T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFβ) signaling mediate superior tumor regression in an animal model of adoptive cell therapy. J Transl Med. 2012;10:127. https://doi.org/10.1186/1479-5876-10-127.CrossRefPubMedPubMedCentral

86.

Scanlan MJ, Mohan Raj BK, Calvo B, Garin-Chesa P, Sanz-Moncasi MP, Healey JH, et al. Molecular cloning of fibroblast activtion proteinα, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci USA. 1994;91:5657–61.CrossRefPubMedPubMedCentral

87.

Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci USA. 1990;87:7235–9.CrossRefPubMedPubMedCentral

88.

Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee CC, Restifo NP, et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210:1125–35.CrossRefPubMedPubMedCentral

89.

Kakarla S, Chow KKH, Mata M, Shaffer DR, Song XT, Wu MF, et al. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma. Mol Ther. 2013;21:1611–20.CrossRefPubMedPubMedCentral

90.

Schuberth PC, Hagedorn C, Jenesen SM, Gulati P, van den Broek M, Mischo A, et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J Transl Med. 2013;11:187.CrossRefPubMedPubMedCentral

91.

Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, Antzis M, Cotner CE, Johnson LA, Durham AC, et al. Targeting fibroblast activation protein intumor stroma with chimeric antigen receptor T cells can inhibit tumorgrowth and augment host immunity without severe toxicity. Cancer Immunol Res. 2014;2:154–66.CrossRefPubMed

92.

Lo A, Wang LC, Scholler J, Monslow J, Avery D, Newick K, O’Brien S, Evans RA, Bajor DJ, Clendenin C, et al. Tumor-promoting desmoplasia is disruptedby depleting FAP-expressing stromal cells. Cancer Res. 2015;75:2800–10.CrossRefPubMedPubMedCentral

93.

John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK. Anti-PD-1 antibody therapy potentlenhances the eradication of established tumors by gene-modified T cells.Clin. Cancer Res. 2013;19:5636–46.

94.

Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Pure E, Milone MC, et al. Multifactorial T-cell hypofunction that isreversible can limit the efficacy of chimeric antigen receptor-transducedhuman T cells in solid tumors. Clin Cancer Res. 2014;20:4262–73.CrossRefPubMedPubMedCentral

95.

Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, Newick K, Lo A, June CH, Zhao Y, Moon EK. A chimeric switch-receptor targeting PD1 augmentsthe efficacy of second-generation CAR T cells in advanced solid tumors. Cancer Res. 2016;76:1578–90.CrossRefPubMedPubMedCentral

96.

Prosser ME, Brown CE, Shami AF, Forman SJ, Jensen MC. Tumor PD-L1 costimulatesprimary human CD8(+) cytotoxic T cells modified to express aPD1:CD28 chimeric receptor. Mol Immunol. 2012;51:263–72.CrossRefPubMed

97.

Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, et al. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther. 2017;25(1):249–58. https://doi.org/10.1016/j.ymthe.2016.10.016.CrossRefPubMedPubMedCentral

98.

Zhang X, Sun S, Hwang I, Tough DF, Sprent J. Potent and selective stimulation of memory-phenotype CD8 + T cells in vivo by IL-15. Immunity. 1998;8(5):591–9.CrossRefPubMed

99.

Teague RM, et al. Interleukin-15 rescues tolerant CD8 + T cells for use in adoptive immunotherapy of established tumors. Nat Med. 2006;12(3):335–41.CrossRefPubMed

100.

Klebanoff CA, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8 + T cells. Proc Natl Acad Sci USA. 2004;101(7):1969–74.CrossRefPubMedPubMedCentral

101.

Hurton LV, Singh H, Najjar AM, et al. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci USA. 2016;113(48):E7788-E7797. https://doi.org/10.1073/pnas.1610544113.CrossRefPubMedPubMedCentral

Titel: Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors
verfasst von: Vishal Jindal
Ena Arora
Sorab Gupta
Publikationsdatum: 01.06.2018
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 6/2018
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-018-1149-9

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors

Abstract

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Current status of enhanced recovery after surgery (ERAS) protocol in gastrointestinal surgery

Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt

Asymptomatic recurrence detection and cost-effectiveness in urothelial carcinoma

Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma

A review of HPRT and its emerging role in cancer

Ambient air emissions of polycyclic aromatic hydrocarbons and female breast cancer incidence in US

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Onkologie